Search | Clinical Trials Finder

Conditions: Metabolically Healthy Obesity
Interventions: Inulin Supplementation, Maltodextrin (Placebo), High-fat meal; Dietary Supplement · Other
Lead sponsor: Ball State University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Muncie, Indiana

Conditions: Myotonic Dystrophy
Interventions: Mexiletine, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Accidental Falls
Interventions: Tailored home intervention, Sham intervention; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 65 Years and older
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Psoriasis
Interventions: peficitinib, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 11
States / cities: Birmingham, Alabama • San Diego, California • Miami, Florida + 8 more

Conditions: Perennial Allergic Rhinitis, PAR
Interventions: ciclesonide nasal aerosol, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 7
States / cities: Costa Mesa, California • Stockbridge, Georgia • Normal, Illinois + 4 more

Conditions: HIV Infections
Interventions: Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part A and C: Placebo, Part B: Treatment A, Part B: Treatment B, Part B: Treatment C, Part B: Treatment D, Part B: Treatment E, Part D: Probe cocktail; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ocular Inflammation and Pain After Cataract Surgery
Interventions: APP13007, 0.05%, Matching Vehicle Placebo for APP13007, 0.05%; Drug
Lead sponsor: Formosa Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 31
States / cities: Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 28 more

Conditions: Insomnia
Interventions: Light Exposure, Placebo; Other
Lead sponsor: Northwestern University; Other
Eligibility: 55 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Infections, Meningococcal
Interventions: MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo, MenB vaccine, MenACWY vaccine; Combination Product · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 50 Years
Enrollment: 1,440 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 12
States / cities: Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more

Conditions: Myopia
Interventions: Atropine, Spectacles with HAL, Placebo Eyedrops; Drug · Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 5 Years to 11 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 17
States / cities: Birmingham, Alabama • Tucson, Arizona • Fullerton, California + 12 more

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: Canagliflozin, Placebo; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 54
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more

Conditions: Aging, Frail Older Adults
Interventions: CP-424,391; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years to 84 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 12
States / cities: Palo Alto, California • San Diego, California • Hamden, Connecticut + 9 more

Conditions: Axial Spondyloarthrithis, Ankylosing Spondylitis
Interventions: Certolizumab Pegol, Placebo; Biological · Other
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 16
States / cities: Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 13 more

Conditions: Necrotizing Enterocolitis
Interventions: IBP-9414, Placebo; Drug
Lead sponsor: Infant Bacterial Therapeutics; Industry
Eligibility: Up to 48 Hours
Enrollment: 2,158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 54
States / cities: Tucson, Arizona • Little Rock, Arkansas • Loma Linda, California + 44 more

Conditions: Obese, Obesity
Interventions: HM15275, Placebo of HM15275; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 14
States / cities: Chula Vista, California • Oak Lawn, Illinois • Ames, Iowa + 10 more

Conditions: Cannabis, Low Back Pain, Neuropathic Pain
Interventions: Placebos, dronabinol, Vaporized Cannabis 3.7% THC/5.6% CBD; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 19 Years to 70 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: San Diego, California

Conditions: Relapsing Multiple Sclerosis
Interventions: Ozanimod, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: Berkeley, California • Fresno, California • Sacramento, California + 3 more

Conditions: Systemic Lupus Erythematosus
Interventions: Ianalumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 22
States / cities: Anniston, Alabama • Burbank, California • La Jolla, California + 19 more

Conditions: Herpes Zoster
Interventions: Herpes Zoster vaccine GSK1437173A, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,877 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 23
States / cities: Duarte, California • San Francisco, California • Aurora, Colorado + 16 more

Conditions: Pain, Postoperative
Interventions: Ibuprofen 600 mg, Local anesthetic Group 1, Placebo oral capsule, Local anesthetic Control; Drug
Lead sponsor: Satheesh Elangovan; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: ABT-089, placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 6 Years to 12 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 13
States / cities: Little Rock, Arkansas • Bradenton, Florida • Jacksonville, Florida + 10 more

Conditions: Cerebral Palsy
Interventions: Standardized Constraint-Induced Movement Therapy, Vibration, Placebo (for vibration); Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 3 Years to 9 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Depression
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 46
States / cities: Birmingham, Alabama • Anaheim, California • Cerritos, California + 41 more

Conditions: HIV Preexposure Prophylaxis
Interventions: ISL, FTC/TDF, FTC/TAF, Placebo to ISL, Placebo to FTC/TDF, Placebo to FTC/TAF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 494 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more

Search by objective public record fields.

Gut, Immune, and Vascular Health in Metabolically Healthy Obesity

Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1

The Effectiveness of a Fall Prevention Program

A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis

Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study

Noradrenergic Dysregulation, Sleep and Cognition in Older Adults With Insomnia

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo

IBP-9414 for the Prevention of Necrotizing Enterocolitis - The Connection Study

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

Trial of Dronabinol and Vaporized Cannabis in Chronic Low Back Pain

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A

Pre-Emptive Analgesia in Dental Implant Surgery

Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Sensory Stimulation During CIMT

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)